Bristol-Myers Squibb Co.

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company's products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. The company manufactures products in the United States and Puerto Rico and has manufacturing operations in two foreign countries. The company has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. The company's pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.
  • TickerBMY
  • ISINUS1101221083
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Valens Research
  • Valens Research
BMY Bristol-Myers S... (Health Care)

BMY - Embedded Expectations Analysis - 2021 07 06

Bristol-Myers Squibb Company (BMY:USA) currently trades below historical averages relative to UAFRS-based (Uniform) earnings, with a 6.1x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about their growth opportunities, new product launches, and Opdivo and Yervoy demand Specifically, management may be exaggerating their future growth opportunities, the strength of their balance sheet, and the success of new product launches. Moreover, they may have concerns about trial efficacy and utilization readouts, the potential o...

BMY Bristol-Myers S... (Health Care)

BRISTOL MYERS SQUIBB is slightly downgraded to Slightly Positive due t...

The independent financial analyst theScreener just slightly lowered the general evaluation of BRISTOL MYERS SQUIBB (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date June 25, 2021, the closing price was USD 66.74 and its potential was estimated at USD 72....

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BMY Bristol-Myers S... (Health Care)

Bristol Myers Squibb Co: 2 directors

Two Directors at Bristol Myers Squibb Co sold 16,118 shares at between 65.000USD and 65.250USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under list...

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Valens Research
  • Valens Research
BMY Bristol-Myers S... (Health Care)

BMY - Embedded Expectations Analysis - 2021 07 06

Bristol-Myers Squibb Company (BMY:USA) currently trades below historical averages relative to UAFRS-based (Uniform) earnings, with a 6.1x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about their growth opportunities, new product launches, and Opdivo and Yervoy demand Specifically, management may be exaggerating their future growth opportunities, the strength of their balance sheet, and the success of new product launches. Moreover, they may have concerns about trial efficacy and utilization readouts, the potential o...

BMY Bristol-Myers S... (Health Care)

BRISTOL MYERS SQUIBB is slightly downgraded to Slightly Positive due t...

The independent financial analyst theScreener just slightly lowered the general evaluation of BRISTOL MYERS SQUIBB (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date June 25, 2021, the closing price was USD 66.74 and its potential was estimated at USD 72....

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BMY Bristol-Myers S... (Health Care)

Bristol Myers Squibb Co: 2 directors

Two Directors at Bristol Myers Squibb Co sold 16,118 shares at between 65.000USD and 65.250USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under list...

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Valens Research
  • Valens Research
BMY Bristol-Myers S... (Health Care)

BMY - Embedded Expectations Analysis - 2021 07 06

Bristol-Myers Squibb Company (BMY:USA) currently trades below historical averages relative to UAFRS-based (Uniform) earnings, with a 6.1x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about their growth opportunities, new product launches, and Opdivo and Yervoy demand Specifically, management may be exaggerating their future growth opportunities, the strength of their balance sheet, and the success of new product launches. Moreover, they may have concerns about trial efficacy and utilization readouts, the potential o...

BMY Bristol-Myers S... (Health Care)

BRISTOL MYERS SQUIBB is slightly downgraded to Slightly Positive due t...

The independent financial analyst theScreener just slightly lowered the general evaluation of BRISTOL MYERS SQUIBB (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date June 25, 2021, the closing price was USD 66.74 and its potential was estimated at USD 72....

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BMY Bristol-Myers S... (Health Care)

Bristol Myers Squibb Co: 2 directors

Two Directors at Bristol Myers Squibb Co sold 16,118 shares at between 65.000USD and 65.250USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under list...

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Valens Research
  • Valens Research
BMY Bristol-Myers S... (Health Care)

BMY - Embedded Expectations Analysis - 2021 07 06

Bristol-Myers Squibb Company (BMY:USA) currently trades below historical averages relative to UAFRS-based (Uniform) earnings, with a 6.1x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about their growth opportunities, new product launches, and Opdivo and Yervoy demand Specifically, management may be exaggerating their future growth opportunities, the strength of their balance sheet, and the success of new product launches. Moreover, they may have concerns about trial efficacy and utilization readouts, the potential o...

BMY Bristol-Myers S... (Health Care)

BRISTOL MYERS SQUIBB is slightly downgraded to Slightly Positive due t...

The independent financial analyst theScreener just slightly lowered the general evaluation of BRISTOL MYERS SQUIBB (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date June 25, 2021, the closing price was USD 66.74 and its potential was estimated at USD 72....

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BMY Bristol-Myers S... (Health Care)

Bristol Myers Squibb Co: 2 directors

Two Directors at Bristol Myers Squibb Co sold 16,118 shares at between 65.000USD and 65.250USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under list...

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Valens Research
  • Valens Research
BMY Bristol-Myers S... (Health Care)

BMY - Embedded Expectations Analysis - 2021 07 06

Bristol-Myers Squibb Company (BMY:USA) currently trades below historical averages relative to UAFRS-based (Uniform) earnings, with a 6.1x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about their growth opportunities, new product launches, and Opdivo and Yervoy demand Specifically, management may be exaggerating their future growth opportunities, the strength of their balance sheet, and the success of new product launches. Moreover, they may have concerns about trial efficacy and utilization readouts, the potential o...

BMY Bristol-Myers S... (Health Care)

BRISTOL MYERS SQUIBB is slightly downgraded to Slightly Positive due t...

The independent financial analyst theScreener just slightly lowered the general evaluation of BRISTOL MYERS SQUIBB (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date June 25, 2021, the closing price was USD 66.74 and its potential was estimated at USD 72....

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BMY Bristol-Myers S... (Health Care)

Bristol Myers Squibb Co: 2 directors

Two Directors at Bristol Myers Squibb Co sold 16,118 shares at between 65.000USD and 65.250USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under list...

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Valens Research
  • Valens Research
BMY Bristol-Myers S... (Health Care)

BMY - Embedded Expectations Analysis - 2021 07 06

Bristol-Myers Squibb Company (BMY:USA) currently trades below historical averages relative to UAFRS-based (Uniform) earnings, with a 6.1x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about their growth opportunities, new product launches, and Opdivo and Yervoy demand Specifically, management may be exaggerating their future growth opportunities, the strength of their balance sheet, and the success of new product launches. Moreover, they may have concerns about trial efficacy and utilization readouts, the potential o...

BMY Bristol-Myers S... (Health Care)

BRISTOL MYERS SQUIBB is slightly downgraded to Slightly Positive due t...

The independent financial analyst theScreener just slightly lowered the general evaluation of BRISTOL MYERS SQUIBB (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date June 25, 2021, the closing price was USD 66.74 and its potential was estimated at USD 72....

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

BMY Bristol-Myers S... (Health Care)

Bristol Myers Squibb Co: 2 directors

Two Directors at Bristol Myers Squibb Co sold 16,118 shares at between 65.000USD and 65.250USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under list...

BMY Bristol-Myers S... (Health Care)

Bristol-Myers Squibb Company - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch